CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CervoMed (CRVO) reported results for a new 50 mg neflamapimod tablet and FDA removal of its prior drug-exposure limit.
In a Phase 1 study that met its primary objectives, a single tablet produced similar overall plasma exposure to the prior 40 mg capsule. Its peak concentration was approximately 20% lower, while its concentration 12 hours after dosing was approximately 20% higher. A controlled manufacturing process is designed to address variability seen with the earlier capsule. Following a 39-week dog study, the FDA removed the exposure limit that had constrained dosing.
CervoMed plans a 100 mg twice-daily regimen for future trials. Modeling projects approximately 33% higher trough concentration than the 40 mg three-times-daily regimen used in earlier dementia with Lewy bodies trials. The company said clinical data at 80 mg twice daily support the planned regimen’s safety and tolerability.
Positive
- Phase 1 study met its primary objectives for the new 50 mg tablet.
- 50 mg tablet delivered similar overall plasma exposure to the prior 40 mg capsule after a single dose.
- Peak concentration was approximately 20% lower than with the prior 40 mg capsule.
- 12-hour concentration was approximately 20% higher than with the prior 40 mg capsule.
- FDA exposure limit was removed, allowing greater dosing flexibility in future trials.
- 39-week dog study found a no-observed-adverse-effect drug level three-fold above earlier dog studies.
- Controlled manufacturing process enables reproducible, large-scale production of the new tablet.
- 100 mg twice daily is CervoMed’s planned regimen for future trials.
- Approximately 33% higher trough concentration is projected versus the earlier 40 mg three-times-daily regimen.
Negative
- Phase 1 tablet comparison used single doses, rather than the planned twice-daily regimen.
- Prior 40 mg capsule showed manufacturing variability in the Phase 2b RewinD-LB study.
News Explained
The dog-study no-effect threshold was more than 30 times the clinical exposure range cited from prior trials.
After a 39-week dog study established a no-observed-adverse-effect level more than 30 times the clinical exposure range cited from earlier trials, the FDA removed neflamapimod’s prior plasma-exposure limit, allowing CervoMed to plan 100 mg twice-daily dosing in future trials.
The tablet uses the most stable crystalline form to address manufacturing variability seen with the 40 mg capsule used in RewinD-LB; the company says its controlled process enables reproducible large-scale tablet production.
For the planned 100 mg twice-daily regimen, CervoMed expects similar overall exposure to 80 mg twice daily, with higher trough and lower peak levels; the company says prior analyses associate clinical activity more with trough levels and safety and tolerability more with peak levels.
Details
Market move: CRVO +5.12% in the Sep 28 session. Neflamapimod pharmacokinetic results
On Sep 28, the day this news came out, CRVO closed 5.12% above the previous close. Argus tracked a peak move of +2.6% during that session. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 28 session.
Key Figures
- Tablet strength
- 50 mg
- New neflamapimod oral tablet formulation
- Peak plasma concentration change
- Approximately 20% lower
- 50 mg tablet versus prior 40 mg capsule after single-dose administration
- 12-hour plasma concentration change
- Approximately 20% higher
- Ctrough with BID dosing, 50 mg tablet versus prior 40 mg capsule
- NOAEL exposure versus prior dog studies
- Three-fold higher
- 39-week dog toxicology study
- NOAEL exposure versus active clinical range
- More than 30-fold higher
- 39-week dog toxicology study compared with pharmacologically and clinically active exposure range
- Planned regimen
- 100 mg BID
- Regimen CervoMed plans to advance in future clinical trials
- Modeled trough concentration increase
- Approximately 33%
- Expected versus the 40 mg TID regimen used in prior trials
Historical Context
-
AAIC analyses supported a 50 mg three-times-daily dose for planned Phase 3 DLB testing
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pharmacokinetic medical
cmax medical
ctrough medical
no-observed-adverse-effect level medical
cmc technical
pk-pd medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
FDA removal of the prior drug exposure limit provides greater dosing flexibility in
future clinical trials
CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials
BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. ("CervoMed" or the "Company") (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced pharmacokinetic (PK), regulatory, and manufacturing advances that enable a higher-dose, twice-daily (BID) oral regimen of neflamapimod in future clinical trials.
The developments include a new neflamapimod 50 mg oral tablet formulation with a PK profile favorable for twice-daily dosing, the U.S. Food and Drug Administration’s (FDA) removal of the previous plasma drug exposure limit, and the implementation of a controlled manufacturing process designed to support reproducible, large-scale tablet production.
“The new 50 mg tablet addresses the formulation issue identified during the Phase 2b RewinD-LB study and we intend to move forward with it in future clinical development,” said John J. Alam, M.D., Chief Executive Officer of CervoMed. “Combined with the FDA’s removal of the prior exposure limit, the new pharmacokinetic profile enables us to advance a 100 mg twice-daily regimen that we expect will achieve substantially higher trough drug concentrations than those associated with clinical activity in previous trials, while reducing dosing frequency from three times to twice daily. These developments substantially reduce both clinical execution and manufacturing risk as we move the neflamapimod program forward.”
Supporting Data and Details
Formulation and manufacturing: New 50 mg tablet
The new 50 mg tablet contains the most stable crystalline form of neflamapimod, addressing the manufacturing variability seen with the 40 mg capsule used in the Phase 2b RewinD-LB study. This updated formulation is designed to provide a consistent drug product for future trials and, if approved, commercial supply. The new controlled manufacturing process enables reproducible, large-scale production of the tablet, thus reducing chemistry, manufacturing and controls (CMC) risk.
The new tablet was evaluated in a Phase 1 food-effect and drug-exposure study that met its primary objectives. After single-dose administration, the 50 mg tablet and the prior 40 mg capsule (previously referred to as “DP Batch B”) produced similar overall plasma drug exposure. However, the new tablet demonstrated a PK profile better suited to BID administration, with approximately
Regulatory: FDA removal of drug exposure limit
A 39-week dog toxicology study completed in the first half of 2026 established a no-observed-adverse-effect level (NOAEL) based on plasma drug levels, that was three-fold higher than in prior dog toxicology studies, and more than 30-fold higher than the pharmacologically and clinically active exposure range observed in previously completed clinical trials of neflamapimod in central nervous system disorders. After reviewing these data, the FDA removed the plasma drug exposure limit that had constrained neflamapimod dosing, providing CervoMed greater dosing flexibility in future clinical trials.
Dose selection: 100 mg twice daily
Based on the observed PK profile and pharmacokinetic pharmacodynamic (PK-PD) relationships across the neflamapimod clinical trials, CervoMed plans to advance a 100 mg BID regimen in future clinical trials. PK modeling indicates that the higher daily dose is expected to increase trough plasma drug concentrations by approximately
The clinical safety and tolerability of the planned higher dose regimen are further supported by clinical data with neflamapimod administered at 80 mg BID (two 40 mg capsules), presented at the Alzheimer’s Association International Conference (AAIC) in July 2026. Compared with 80 mg BID, the planned 100 mg BID tablet regimen is expected to provide similar overall plasma drug exposure, with a higher Ctrough and lower Cmax.
These PK characteristics are particularly relevant to neflamapimod because previously reported PK-PD analyses indicate that clinical activity is associated with Ctrough, while safety and tolerability are more closely related to Cmax. The planned regimen is therefore designed to increase pharmacologically relevant trough concentrations without a commensurate increase in peak drug exposure.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding (through a strategic partnership or otherwise) for any Phase 3 trial in patients with DLB; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, ALS, or any other indication, including the degree of sustainability of any therapeutic effects, its potential impact on the rate of disease progression and/or clinical worsening, the optimal dosing regimen to achieve therapeutic effects, or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure, the expected pharmacokinetic profile, drug exposure, or other characteristics of the new 50 mg tablet formulation or the planned 100 mg twice-daily dosing regimen, including initial biomarker data from the Company’s Phase 2a trial in nfvPPA; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB or the impact, if any, of the Innovation Passport Designation on any future regulatory milestone or the timing thereof; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; and any other expected or implied benefits, results, or expectations, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients with DLB or in any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
Contacts
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.